⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026
globenewswire.com
AZN
LLY
REGN
IONS
MRK
XRTX
DMAC
LSTA
Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
BNTX
ASO
IONS
BIIB
ALT
TEVA
TENX
UTHR
PFE
UNH
ABBV
GOSS
INSM
Global Value-Based Healthcare Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight
globenewswire.com
PFE
BNTX
ALNY
IONS
ARCT
GOOGL
MSFT
AMZN
INTC
GEHC
RHP
IBM
AAPL
MCK
IQV
ORCL
HON
HPQ
RNA Therapeutics Market Size, Share & Trends Analysis - Global Forecast to 2036
globenewswire.com
MRNA
BNTX
CVAC
ALNY
IONS
ARWR
REGN
SRPT
SLN
BEAM
NTLA
CRSP
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
globenewswire.com
ALNY
IONS
SRPT
BIIB
NVS
AZN
NVO
SNY
ARWR
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
TLRY
TAK
TNDM
NVS
BMY
PFE
INCY
JNJ
AZN
MRK
ABBV
CRSP
SCLX
RIGL
JAZZ
GILD
REGN
AMGN
BIIB
PTGX
EXAS
SNOW
SRPT
VRTX
BNTX
ALKS
RGEN
IMUX
ADPT
ATRC
CRNX
CYTK
DTIL
EXEL
FGEN
GALT
GNTX
GRFS
GSK
HRMY
IDXX
ILMN
INSM
IONS
IRWD
KODK
LAKE
LULU
LYFT
MAR
MDLZ
MELI
MIRM
MNKD
MRNA
MTCH
NBIX
NCLH
NEM
NTRA
NVCR
ODFL
OMER
ORGO
OTEX
PACB
PBYI
PCAR
PEGA
PERI
PETS
PLRX
PMVP
PPC
PRGS
PRTA
PSNL
PTN
PZZA
QGEN
QTRX
RARE
RCEL
RDHL
RLAY
RLGT
RMD
ROST
RRX
RYAAY
RYTM
SAN
SBAC
SBRA
SEIC
SIGA
SIRI
SITE
SLAB
SLGN
SMCI
SMMT
SNPS
SNY
SOFI
SONO
SPCE
SSYS
STNG
STRA
STRL
STX
SWKS
SYK
SYNA
TCOM
TDOC
TECK
TEVA
TFX
TGTX
TIGR
TRMB
TRVG
TTWO
TUSK
TXRH
ULTA
UMC
UNFI
UNH
URBN
UTHR
VEEV
VELO
VERU
VIVO
VKTX
VLRS
VNDA
VRSK
VSAT
VTGN
WDC
WEC
WERN
WGO
WIX
WMB
WST
WTW
WYNN
XOM
XPER
XPO
XRAY
YETI
YRD
YUM
ZBRA
ZLAB
ZYME
Form 8-K
sec.gov
IONS
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
businesswire.com
IONS
Form 8-K
sec.gov
IONS
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
globenewswire.com
NTLA
REGN
ALNY
IONS
PFE